Skip to main content
VCbacked
Log inGet Started

Nacuity Pharmaceuticals

Fort Worth, United States

Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.

$16.5M raised
Jun 2022
Series B
Health CarePharmaceutical

Top Investors

Foundation Fighting BlindnessMaxim GroupRetinal Degeneration FundHugo Peris

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Nacuity Pharmaceuticals

How much funding has Nacuity Pharmaceuticals raised?
Nacuity Pharmaceuticals has raised $16.5M in total funding. The most recent round was Series B. The last funding was announced in June 2022.
Who are Nacuity Pharmaceuticals's investors?
Nacuity Pharmaceuticals's investors include Foundation Fighting Blindness, Maxim Group, Retinal Degeneration Fund, Hugo Peris.
Where is Nacuity Pharmaceuticals headquartered?
Nacuity Pharmaceuticals is headquartered in Fort Worth, United States.
What does Nacuity Pharmaceuticals do?
Nacuity Pharmaceuticals is a pharmaceutical company that aims to develop a breakthrough treatment for retinitis pigmentosa.
What stage is Nacuity Pharmaceuticals at?
Nacuity Pharmaceuticals is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Nacuity Pharmaceuticals — Funding & Investors." VCBacked, June 15, 2022, https://www.vcbacked.co/company/nacuity-pharmaceuticals. Accessed July 2, 2026.
APA
VCBacked. (2022). Nacuity Pharmaceuticals — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/nacuity-pharmaceuticals
Wikipedia (cite web)
{{cite web |title=Nacuity Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/nacuity-pharmaceuticals |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Health Care

View all
Oryl Photonics
Lausanne
Allterum Therapeutics
Houston$1.0M
OncoRevive
Brunswick$119K
Rapport Therapeutics
Boston$250.0M
YLAH
Bern$589K
Novostia
Epalinges$6.6M